Breaking News
Get Actionable Insights with InvestingPro+: Start 7 Day FREE Trial Register here
Investing Pro 0
Ad-Free Version. Upgrade your experience. Save up to 40% More details

Fresenius (FMS) Acquires 70% Stake In Kunming Wuhua Hospital

By Zacks Investment ResearchStock MarketsApr 06, 2017 09:49PM ET
Fresenius (FMS) Acquires 70% Stake In Kunming Wuhua Hospital
By Zacks Investment Research   |  Apr 06, 2017 09:49PM ET
Saved. See Saved Items.
This article has already been saved in your Saved Items

Leading provider of dialysis products and services, Fresenius Medical Care AG & Co. KGAA (NYSE:FMS) , announced the acquisition of 70% equity interest in Kunming Wuhua Health Hospital in China. This is Fresenius Medical Care's first joint venture hospital in China.

Stock Performance

In the last three months, the price performance of Fresenius Medical was encouraging. The stock added 5.01% versus the Zacks classified Medical Instruments sub-industry’s gain of 4.71%.

However, the estimates revision trend for the stock lacks luster. The current quarter saw one estimate moving south over the last month, with no movement in the opposite direction. As a result, the Zacks Consensus Estimate for the current quarter dropped to 44 cents per share from 45 cents over the same time period.

More About the China Venture

Wuhua Hospital is a private Grade II hospital located in Wuhua district in the center of Kunming city. It is the capital of Yunnan province in south-west China.

The facility provides treatments to more than 8,000 chronic-disease patients and 70 dialysis patients. The scope of services includes internal medicine, nephrology, surgery, gynecology, dermatology, traditional Chinese medicine, physiotherapy, stomatology and others.

Fresenius Medical Care is a leading healthcare company, focusing on providing care to people with renal and other chronic conditions. The company has an extensive network of dialysis facilities, outpatient cardiac and vascular labs, urgent care centers, and the country’s largest collection of hospitalist and post-acute providers.

One of the world’s largest fully vertically integrated renal company, it offers specialty pharmacy and laboratory services, and manufactures and distributes the most comprehensive line of dialysis equipment, disposable products, and renal pharmaceuticals.

Key Picks

Currently, Fresenius Medical carries a Zacks Rank #3 (Hold). Better-ranked stocks in the broader medical sector are Inogen Inc. (NASDAQ:INGN) , IDEXX Laboratories, Inc. (NASDAQ:IDXX) and Fluidigm Corporation (NASDAQ:FLDM) . Notably, Inogen and IDEXX Laboratories sport a Zacks Rank #1 (Strong Buy) while Fluidigm carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.

Inogen has a long-term expected earnings growth rate of 17.50%. Notably, the stock registered an impressive one-year return of 70.6%.

IDEXX Laboratories has a long-term expected earnings growth rate of 15.04%. Additionally, the stock returned an impressive 97.5% in the last one year.

Fluidigm has a long-term expected earnings growth rate of 25%. The stock delivered a positive earnings surprise of 1.6% last quarter.

Zacks’ Best Private Investment Ideas

While we are happy to share many articles like this on the website, our best recommendations and most in-depth research are not available to the public.

Starting today, for the next month, you can follow all Zacks' private buys and sells in real time. Our experts cover all kinds of trades… from value to momentum . . . from stocks under $10 to ETF and option moves . . . from stocks that corporate insiders are buying up to companies that are about to report positive earnings surprises. You can even look inside exclusive portfolios that are normally closed to new investors. Click here for Zacks' private trades >>

Fresenius Medical Care Corporation (FMS): Free Stock Analysis Report

IDEXX Laboratories, Inc. (IDXX): Free Stock Analysis Report

Inogen, Inc (INGN): Free Stock Analysis Report

Fluidigm Corporation (FLDM): Free Stock Analysis Report

Original post

Zacks Investment Research
Fresenius (FMS) Acquires 70% Stake In Kunming Wuhua Hospital

Related Articles

Fresenius (FMS) Acquires 70% Stake In Kunming Wuhua Hospital

Add a Comment

Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at’s discretion.

Write your thoughts here
Are you sure you want to delete this chart?
Post also to:
Replace the attached chart with a new chart ?
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
Are you sure you want to delete this chart?
Replace the attached chart with a new chart ?
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn`t bear any responsibility for any trading losses you might incur as a result of using this data.

Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.
Continue with Google
Sign up with Email